Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Advanced or Metastatic Solid TumorsCancerSolid Cancers
- Interventions
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Semafore Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT00907205
- Locations
- 🇺🇸
Scottsdale Clinical Research Institute, Scottsdale, Arizona, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
News
No news found